ReviewExperientia supplementum (2012)2026
Role of SLC Transporters and Noncoding RNA in Regulating the Genetic Landscape of the Blood Disorders.
Review in Experientia supplementum (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complex interplay between solute carrier (SLC) transporters and noncoding RNAs (ncRNAs) in regulating genetic and metabolic pathways in hematological disorders remains underexplored. This chapter addresses the critical need to understand how these regulators influence the development, progression, and therapeutic resistance of leukemia. By elucidating these mechanisms, this chapter aims to contribute to the development of novel, targeted interventions for improved clinical outcomes. This chapter delves into the multifaceted roles of SLC transporters and ncRNAs in blood cell regulation, highlighting their impact on hematopoiesis and leukemogenesis. Topics include the hierarchical differentiation of hematopoietic stem cells, the molecular subtypes of leukemia, and the regulatory roles of transcription factors and chromatin modifiers in leukemia progression. Additionally, this chapter explores how SLC transporters mediate nutrient uptake, drug resistance, and metabolic adaptations in leukemic cells. It further examines the involvement of ncRNAs-such as microRNAs, long noncoding RNAs, and circular RNAs-in modulating transporter activity, impacting both normal and malignant hematopoietic processes. Through these discussions, this chapter offers critical insights into the therapeutic potential of targeting SLC transporters and ncRNAs in leukemia treatment. It underscores the importance of understanding the genetic and epigenetic landscapes of blood disorders to develop precision medicine approaches. By integrating recent advancements and highlighting gaps in knowledge, this chapter provides a foundation for future research aimed at overcoming the challenges of multidrug resistance and enhancing treatment efficacy in hematological malignancies.
Indexed as
Identifiers
41479111What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.